A Targeted Therapy Next in Line for Biomarker-based Cancer Drug Approval?

recent data suggest that there is another potential contender for a biomarker-based FDA approval: a targeted therapeutic called larotrectinib (LOXO-101), which showed promising results in adults and children with a variety of cancer types, all of which had one thing in common – fusions involving the gene TRK.

Read More

Catching Childhood Cancers Early: Insights Into the AACR Childhood Cancer Predisposition Workshop

There is perhaps nothing more painful for parents than receiving a cancer diagnosis for their child. Childhood cancers are generally rare, and in the United States, the death rates have …

Read More

Heading Into Summer, Please “Don’t Fry”

Today is National “Don’t Fry Day,” an initiative undertaken by the National Council on Skin Cancer Prevention to encourage sun safety awareness and to remind people to limit their exposure to ultraviolet (UV) radiation, which has been proven to cause skin cancer.

Read More

FDA Approves First Use for an Anticancer Therapeutic Based on Tumor Biomarker, Not Tumor Origin

Tuesday marked a milestone for the oncology community: The U.S. Food and Drug Administration (FDA) announced its first approval of an anticancer therapeutic for use based on whether a patient has a tumor with certain biomarkers and not where in the body the tumor originated.

Read More

Scientist↔Survivor Program Participants Spend a Memorable Day on Capitol Hill

US Capitol Building

May is National Cancer Research Month, and for the past 10 years, leaders and members from the American Association for Cancer Research (AACR), the Association of American Cancer Institutes (AACI), and the American Society of Clinical Oncology (ASCO) have converged on Capitol Hill during May to share how cancer research is saving lives and transforming patient care.

Read More

AACR Annual Meeting 2017: The Patient Perspective

The American Association for Cancer Research (AACR) Annual Meeting 2017 brought some of the world’s greatest scientific minds to Washington, D.C., to address research challenges in cancer. But significant findings also came from cancer patient advocates and survivors who attended the meeting.

Read More

AACR Annual Meeting 2017: Most Merkel Cell Carcinoma Responses to the Newly FDA-Approved Avelumab Expected to Last More than a Year

T cells and antibodies

On March 23, the U.S. Food and Drug Administration announced the first-ever approval of a treatment for patients with a rare, aggressive form of skin cancer called Merkel cell carcinoma. The treatment, the immunotherapeutic avelumab (Bavencio), was approved based on data from the JAVELIN Merkel 200 phase II clinical trial.

Read More

“No Time to Stop the Momentum”

Former Vice President Joe Biden returned to the stage at the American Association for Cancer Research (AACR) Annual Meeting on Monday, sounding a battle cry to continue the momentum for cancer research that began when he launched the National Cancer Moonshot Initiative in 2016.

Read More

Public Policy and Advocacy in Cancer Research: An Associate Member Guest Post

April symbolizes a progressive time for cancer researchers around the world. From April 1-5, over 20,000 cancer scientists will gather in Washington, D.C., to attend the American Association for Cancer Research (AACR) 2017 Annual Meeting.

Read More